QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.060129v1 308/3/1191    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Canbay, A. Articles by Gores, G. J. Search for Related Content PubMed PubMed Citation Articles by Canbay, A. Articles by Gores, G. J.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse

Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic, and Foundation, Rochester, Minnesota

Liver injury is characterized by hepatocyte apoptosis and collagen-producing activated hepatic stellate cells (HSC). Hepatocyte apoptosis promotes liver injury and fibrosis, whereas activated HSC apoptosis limits hepatic fibrosis. Pharmacological inhibition of liver cell apoptosis may potentially attenuate liver injury and fibrosis by blocking hepatocyte apoptosis or promote fibrosis by permitting accumulation of activated HSCs. To ascertain the net effect of inhibiting liver cell apoptosis on liver injury, inflammation, and hepatic fibrogenesis, we examined the effect of a pancaspase inhibition IDN-6556 on these parameters in the bile duct ligated (BDL) mouse. Hepatocyte apoptosis was assessed by the terminal deoxynucleotidyl transferase dUTP nick-end labeling assay and immunofluorescence for active caspases 3/7, and liver injury by histopathology and serum alanine aminotransferase (ALT) determinations. Real-time polymerase chain reaction was used to measure mRNA transcripts for markers of hepatic inflammation, HSC activation, and fibrosis. Immunohistochemistry for -smooth muscle actin was performed to identify HSC activation. Collagen deposition was quantitated by Sirius red staining and digital imaging techniques. Hepatocyte apoptosis and liver injury (bile infarcts and serum ALT values) were reduced in IDN-6556-treated versus saline-treated 3-day BDL mice. Markers for liver inflammation [chemokine (C-X-C) ligand 1 and macrophage inflammatory protein-2 chemokine expression] and hepatic fibrogenesis (transforming growth factor- and collagen I expression) were also attenuated. Consistent with these data, HSC activation as assessed by -smooth muscle actin mRNA expression and immunohistochemistry was markedly reduced in both 3- and 10-day BDL animals. Collectively, these data suggest hepatocyte apoptosis initiates cascades culminating in liver injury and fibrosis. The pan-caspase inhibitor IDN-6556 is a promising agent for cholestatic liver injury.

Address correspondence to: Dr. Gregory J. Gores, Mayo Medical School, Clinic, and Foundation, 200 First St. SW, Rochester, MN 55905. E-mail: gores.gregory{at}mayo.edu

This article has been cited by other articles:

				W. I. Hagens, L. Beljaars, D.A. Mann, M. C. Wright, B. Julien, S. Lotersztajn, C. Reker-Smit, and K. Poelstra Cellular Targeting of the Apoptosis-Inducing Compound Gliotoxin to Fibrotic Rat Livers J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 902 - 910. [Abstract] [Full Text] [PDF]

				S. L. Friedman Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver Physiol Rev, January 1, 2008; 88(1): 125 - 172. [Abstract] [Full Text] [PDF]

				D. R. Jeyarajah, M. L. Kielar, H. Saboorian, P. Karimi, N. Frantz, and C. Y. Lu Impact of bile duct obstruction on hepatic E. coli infection: role of IL-10. Am J Physiol Gastrointest Liver Physiol, July 1, 2006; 291(1): G91 - G94. [Abstract] [Full Text] [PDF]

				R. Greupink, H. I. Bakker, W. Bouma, C. Reker-Smit, D. K. F. Meijer, L. Beljaars, and K. Poelstra The Antiproliferative Drug Doxorubicin Inhibits Liver Fibrosis in Bile Duct-Ligated Rats and Can Be Selectively Delivered to Hepatic Stellate Cells in Vivo J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 514 - 521. [Abstract] [Full Text] [PDF]

				M E Guicciardi and G J Gores Apoptosis: a mechanism of acute and chronic liver injury Gut, July 1, 2005; 54(7): 1024 - 1033. [Full Text] [PDF]

				U. Fischer and K. Schulze-Osthoff New Approaches and Therapeutics Targeting Apoptosis in Disease Pharmacol. Rev., June 1, 2005; 57(2): 187 - 215. [Abstract] [Full Text] [PDF]